Uppsala, Sweden – 12 September 2018
Beactica, the Swedish drug discovery company, today announced that it has been given the Nordic Stars Award 2018. The prize is handed out annually by SwedenBIO, the Swedish association for the life science industry, “in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.” The award was presented to Beactica at the conclusion of the Nordic Life Science Days in Stockholm.
“We are delighted to receive this prestigious recognition from SwedenBIO,” said Per Källblad, CEO of Beactica. “It is foremost a recognition of the great team at Beactica. We are also grateful to our investors and collaboration partners across the world who are making important contributions towards the next breakthrough in oncology.”
The jury’s motivation: “Beactica has through a series of discovery collaborations with global pharmaceutical companies proved to be a trusted partner in fragment-based lead generation. They have also used their proprietary methodologies to pursue their own drug discovery programmes in oncology, attracting widespread interest from both investors and international pharma companies.”
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in areas of unmet medical need, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology. For more information on Beactica, please visit www.beactica.com.
Sign up for the Beactica newsletter to recieve our latest news and updates